Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors

Cancer Biology and Therapy

Volumn 10, Issue 10, 2010, Pages 983-993

  Rüter, Jens ^a   Antonia, Scott J ^b   Burris III, Howard A ^c   Huhn, Richard D ^d   Vonderheide, Robert H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c SARAH CANNON RESEARCH INSTITUTE   (United States)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Antibody; B cell; CD40; Immunotherapy; T cell

Indexed keywords

CP 870893;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANUS CANCER; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BACKACHE; BLADDER CANCER; BREAST CANCER; BRONCHITIS; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; CONFUSION; CONSTIPATION; COUGHING; CYTOKINE RELEASE SYNDROME; DEHYDRATION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; FLUSHING; HEMOPTYSIS; HUMAN; HYPOPHOSPHATEMIA; IMMUNOMODULATION; KIDNEY CARCINOMA; LETHARGY; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHEDEMA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MELANOMA; MESOTHELIOMA; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; NASOPHARYNX CANCER; NAUSEA; NEUROENDOCRINE TUMOR; OVARY CANCER; PAIN; PHASE 1 CLINICAL TRIAL; PLEURITIC PAIN; PROTEIN EXPRESSION; PTOSIS; SIDE EFFECT; SOLID TUMOR; THORAX PAIN; TREATMENT RESPONSE; URTICARIA; UTERUS CANCER;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; ANTINEOPLASTIC AGENTS; CYTOKINES; FEMALE; FLOW CYTOMETRY; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; REMISSION INDUCTION; T-LYMPHOCYTE SUBSETS; TISSUE DISTRIBUTION;

EID: 78549256115     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.10.13251     Document Type: Article

References (26)

1. Vonderheide RH. Prospect of targeting the CD40 pathway for cancer therapy. Clin Cancer Res 2007;13:1083-8.
2. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998; 393:478-80. (Pubitemid 28292195)
3. + T- helper and a T-killer cell. Nature 1998; 393:474-8.
4. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998; 393:480-3. (Pubitemid 128728269)
5. French RR, Chan HT, Tutt AL, Glennie MJ. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med 1999; 5:548-53.
6. Diehl L, den Boer AT, Schoenberger SP, van der Voort EI, Schumacher TN, Melief CJ, et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med 1999; 5:774-9.
7. + T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med 1999; 5:780-7.
8. van Mierlo GJ, den Boer AT, Medema JP, van der Voort EI, Fransen MF, Offringa R, et al. CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci USA 2002; 99:5561-6.
9. Hunter TB, Alsarraj M, Gladue RP, Bedian V, Antonia SJ. An agonist antibody specific for CD40 induces dendritic cell maturation and promotes autologous anti-tumour T-cell responses in an in vitro mixed autologous tumour cell/lymph node cell model. Scand J Immunol 2007; 65:479-86. (Pubitemid 46632548)
10. Carpenter EL, Mick R, Ruter J, Vonderheide RH. Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation. J Transl Med 2009; 7:93.
11. Bedian V, Donovan C, Garder J, Natoli E, Paradis T, Alpert R, et al. In vitro characterization and pre-clinical pharmacokinetics of CP-870,893, a human anti-CD40 agonist antibody. J Clin Oncol 2006; 24:109.
12. Gladue R, Cole S, Donovan C, Paradis T, Alpert R, Natoli E, et al. In vivo efficacy of the CD40 agonist antibody CP-870,893 against a broad range of tumor types: impact of tumor CD40 expression, dendritic cells and chemotherapy. J Clin Oncol 2006; 24:103.
13. Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS, Bajor DL, Hutnick NA, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 2007; 25:876-83.
14. Kedl RM, Jordan M, Potter T, Kappler J, Marrack P, Dow S. CD40 stimulation accelerates deletion of tumor-specific CD8(+) T cells in the absence of tumor-antigen vaccination. Proc Natl Acad Sci USA 2001; 98:10811-6. (Pubitemid 32878702)
15. + T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy. Nat Med 2007; 13:354-60.
16. Hodi FS. Cytotoxic T-lymphocyte-associated antigen-4. Clin Cancer Res 2007; 13:5238-42.
17. Banchereau J, Bazan F, Blanchard D, Briere F, Galizzi JP, van Kooten C, et al. The CD40 antigen and its ligand. Annu Rev Immunol 1994; 12:881-922.
18. Schultze JL, Michalak S, Seamon MJ, Dranoff G, Jung K, Daley J, et al. CD40 activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest 1997; 100:2757-65.
19. Coughlin CM, Vance BA, Grupp SA, Vonderheide RH. RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. Blood 2004; 103:2046-54.
20. Coughlin CM, Fleming MD, Carroll RG, Pawel BR, Hogarty MD, Shan X, et al. Immunosurveillance and survivin-specific T-cell immunity in children with high-risk neuroblastoma. J Clin Oncol 2006; 24:5725-34.
21. Lanzavecchia A. Immunology. Licence to kill. Nature 1998; 393:413-4.
22. Lund FE, Randall TD. Effector and regulatory B cells: modulators of CD4(+) T cell immunity. Nat Rev Immunol 2010; 10:236-47.
23. Bartholdy C, Kauffmann SO, Christensen JP, Thomsen AR. Agonistic anti-CD40 antibody profoundly suppresses the immune response to infection with lymphocytic choriomeningitis virus. J Immunol 2007; 178:1662-70. (Pubitemid 46154638)
24. Mauri C, Mars LT, Londei M. Therapeutic activity of agonistic monoclonal antibodies against CD40 in a chronic autoimmune inflammatory process. Nat Med 2000; 6:673-9.
25. Hussein MA, Berenson JR, Niesvizky R, Munshi NC, Harrop KL, McDonald M, et al. A phase I humanized anti-CD40 monoclonal antibody (SGN-40) in patients with multiple myeloma. Blood 2005; 1060:2572.
26. Advani R, Forero-Torres A, Furman RR, Rosenblatt JD, Younes A, Ren H, et al. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol 2009; 27:4371-7.